Richard Hawkins Biography and Net Worth

Director of Savara

Mr. Hawkins has served as a member of Savara’s Board of Directors since October 2010. Mr. Hawkins currently serves on the Board of Directors of several privately held life sciences companies, as well as Plus Therapeutics Inc. (formerly Cytori Therapeutics, Inc.) and previously served on the Board of Directors of SciClone Pharmaceuticals, Inc. until its acquisition in 2017. Mr. Hawkins served as Chief Executive Officer and Chair of the Board of Directors of Lumos Pharma, Inc., a clinical stage biotechnology company focused on bringing novel therapies to patients with severe, rare, and genetic diseases, whose medical needs are unmet, from 2010 until its acquisition in 2024. Prior to his tenure with Lumos Pharma, Inc., Mr. Hawkins founded and advised numerous pharmaceutical companies, including Sensus, where he served as Co-Founder and Chair of the Board of Directors until it was sold to Pfizer. Previously, he was Founder, President, and Chief Executive Officer of Pharmaco, where he guided the company’s growth to more than 2,000 employees. The company later merged with PPD to form PPD Pharmaco, one of the largest clinical contract research organizations in the world. Mr. Hawkins holds a B.S. in Biology from Ohio University.

What is Richard J. Hawkins' net worth?: The estimated net worth of Richard J. Hawkins is at least $735.52 thousand as of June 20th, 2025. Mr. Hawkins owns 115,466 shares of Savara stock worth more than $735,518 as of December 5th. This net worth evaluation does not reflect any other assets that Mr. Hawkins may own. Learn More about Richard J. Hawkins' net worth.
How old is Richard J. Hawkins?: Mr. Hawkins is currently 68 years old. There are 7 older executives and no younger executives at Savara. Learn More on Richard J. Hawkins' age.
How do I contact Richard J. Hawkins?: The corporate mailing address for Mr. Hawkins and other Savara executives is 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746. Savara can also be reached via phone at 512-614-1848 and via email at [email protected]. Learn More on Richard J. Hawkins' contact information.
Has Richard J. Hawkins been buying or selling shares of Savara?: Richard J. Hawkins has not been actively trading shares of Savara over the course of the past ninety days. Most recently, on Friday, June 20th, Richard J. Hawkins bought 48,225 shares of Savara stock. The stock was acquired at an average cost of $2.04 per share, with a total value of $98,379.00. Following the completion of the transaction, the director now directly owns 115,466 shares of the company's stock, valued at $235,550.64. Learn More on Richard J. Hawkins' trading history.
Who are Savara's active insiders?: Savara's insider roster includes Badrul Chowdhury (Insider), Nevan Elam (Director), Richard Hawkins (Director), David Lowrance (CFO), Joseph Mccracken (Director), Matthew Pauls (CEO), Raymond Pratt (Insider), and David Ramsay (Director). Learn More on Savara's active insiders.
Are insiders buying or selling shares of Savara?: In the last twelve months, Savara insiders bought shares 2 times. They purchased a total of 58,225 shares worth more than $119,179.00. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 54,702 shares worth more than $181,063.62. The most recent insider tranaction occured on June, 20th when Director Richard J Hawkins bought 48,225 shares worth more than $98,379.00. Insiders at Savara own 5.3% of the company. Learn More about insider trades at Savara.
Information on this page was last updated on 6/20/2025.

Richard J. Hawkins Insider Trading History at Savara

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/20/2025	Buy	48,225	$2.04	$98,379.00	115,466
5/15/2019	Sell	25,000	$11.10	$277,500.00	21,682

Richard J. Hawkins Buying and Selling Activity at Savara

Savara Company Overview

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Today's Range

Now: $6.37

$6.18

$6.45

50 Day Range

MA: $4.28

$3.37

$6.37

2 Week Range

Now: $6.37

$1.89

$6.61

Volume

4,976,997 shs

Average Volume

2,496,009 shs

Market Capitalization

$1.30 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.23

Richard Hawkins Biography and Net Worth

What is Richard J. Hawkins' net worth?

How old is Richard J. Hawkins?

How do I contact Richard J. Hawkins?

Has Richard J. Hawkins been buying or selling shares of Savara?

Who are Savara's active insiders?

Are insiders buying or selling shares of Savara?